Literature DB >> 11952243

Pancreatic resection for locally advanced primary and metastatic nonpancreatic neoplasms.

James F Pingpank1, John P Hoffman, Elin R Sigurdson, Eric Ross, Aaron R Sasson, Burton L Eisenberg.   

Abstract

We conducted a retrospective review of our single-institution experience with pancreas resection for locally advanced primary malignancy or metastases from other organs. From January 1989 through April 2001 35 patients underwent pancreatic resection for locally advanced primary (17) and recurrent nonpancreatic (18) tumors. Patient records were examined for recurrence and survival. Seventeen patients with locally advanced primary tumors presented with pancreatic extension either into the head/body (six) or tail (11). Pancreatic resections were completed as en bloc procedures with the primary disease of stomach (five), colon (four), sarcoma (five), adrenal gland (one), or spleen (one). Procedures performed included pancreaticoduodenectomy for proximal lesions and distal pancreatectomy for disease limited to the pancreatic tail. Median overall survival was 56 months. Fourteen of 17 patients remain alive: three with disease and 11 without evidence of recurrence. Eighteen patients presented with recurrent tumor from a previously resected right upper quadrant tumor (nine) or metastases from an intra-abdominal source (nine). The primary source was colon (eight), biliary (three), sarcoma (three), melanoma (two), ovary (one), and unknown primary (one). Patients underwent pancreaticoduodenectomy, distal pancreatectomy, or resection of residual pancreas. Overall median survival was 46 months. In this group of 18 patients there was no increased survival in those patients with a time to recurrence from their primary tumor resection greater than 2 years. We conclude that pancreatic resection for locally advanced nonpancreatic or recurrent intra-abdominal malignancies is possible in properly selected patients. The ability to obtain disease-free margins through en bloc resection is a key component of therapy.

Entities:  

Mesh:

Year:  2002        PMID: 11952243

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  7 in total

1.  Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.

Authors:  Jing-Ting Jiang; Chang-Ping Wu; Hai-Feng Deng; Ming-Yang Lu; Jun Wu; Hong-Yu Zhang; Wen-Hui Sun; Mei Ji
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

2.  Metachronous pancreatic metastasis of an ovarian serous papillary adenocarcinoma after 8 years.

Authors:  Andrea Anderloni; Marco Ballarè; Michela Pagliarulo; Marco Orsello; Antonio Ramponi; Mario Del Piano
Journal:  J Gastrointest Oncol       Date:  2013-12

3.  Late presentation of a mucinous ovarian adenocarcinoma which was initially diagnosed as a primary pancreatic carcinoma: a case report and review of the literature.

Authors:  Dorothy A Sparks; Daniel M Chase; Mark Forsyth; Gregg Bogen; Jon Arnott
Journal:  J Med Case Rep       Date:  2010-03-18

Review 4.  Pancreatic resection for metastatic melanoma. Case report and review of the literature.

Authors:  Cosimo Sperti; Maria Laura Polizzi; Valentina Beltrame; Margherita Moro; Sergio Pedrazzoli
Journal:  J Gastrointest Cancer       Date:  2011-12

5.  Distal pancreatectomy is not associated with increased perioperative morbidity when performed as part of a multivisceral resection.

Authors:  Jennifer L Irani; Stanley W Ashley; David C Brooks; Robert T Osteen; Chandrajit P Raut; Sara Russell; Richard S Swanson; Edward E Whang; Michael J Zinner; Thomas E Clancy
Journal:  J Gastrointest Surg       Date:  2008-08-02       Impact factor: 3.452

6.  Pancreatic resection for metastatic melanoma.

Authors:  M Nikfarjam; P Evans; C Christophi
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

7.  Pancreatectomy for non-pancreatic malignancies results in improved survival after R0 resection.

Authors:  Kimberly A Varker; Peter Muscarella; Kristian Wall; Christopher Ellison; Mark Bloomston
Journal:  World J Surg Oncol       Date:  2007-12-27       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.